Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy.

Trial Profile

Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Germ cell and embryonal neoplasms; Testicular cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2014 Results presented at the 2014 Genitourinary Cancers Symposium.
    • 10 Sep 2010 Status changed from recruiting to completed according to ISRCTN.
    • 09 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top